Overview
This series explains why academic start-up financing is a path rather than a single funding event. It distinguishes founder-based and research-linked definitions, shows how a German EGS grant can increase formal company formation near its threshold, and uses OECD evidence from 81,318 start-ups in 38 countries to examine instruments, timing, follow-on funding, innovation, scale, and exit. The central judgment is conditional: choose grants, assistance, equity, convertibles, or debt for the bottleneck they can relieve, then build the technical, commercial, and network capabilities needed for the next handoff. The EGS result is local and causal under its design; the OECD patterns are adjusted associations, not proof that one instrument causes later outcomes.
Learning outcomes
- A first funding round should match the venture’s current bottleneck and prepare evidence for the next provider.
- Near the German EGS funding threshold, support substantially increased formal company formation; the estimate is local.
- In OECD data, academic start-ups reached grants and assistance earlier, while follow-on funding was lower after observed controls.
- Science-linked patents can grow while scale-up and acquisition remain harder; formation, innovation, funding, and exit are distinct outcomes.
Keywords
Preview every chapter · Unlock full text, audio, and video from chapter 4
PlansFAQ
What should an academic start-up’s first funding round accomplish?
It should relieve the current bottleneck and produce evidence, capability, or relationships that make the next financing source plausible.
Does a grant guarantee follow-on equity for an academic start-up?
No. In the OECD data, first grants were associated with repeat grants, weaker transitions to equity, and lower follow-on funding; the study does not prove grants caused that pattern.
What did the German EGS study show?
For projects near its expert-score threshold, EGS support substantially increased the probability of forming a qualifying company in the German Commercial Register. It did not establish survival or later private funding.
Why can academic start-ups produce patents yet struggle to scale?
Technical innovation does not by itself provide customer evidence, regulatory readiness, commercial capability, investor access, or a buyer-ready route to return. The OECD findings are consistent with this gap but do not identify one universal cause.